TP53 and prostate carcinoma: As the p53 tumour suppressor is frequently mutated in prostate cancer and has prognostic significance [4, 58], future studies should explore whether enhanced sensitivity or/and induction of apoptosis in response to CT7001 treatment is dependent on an intact p53 pathway.